These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6861865)

  • 21. Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia.
    Hoffmann E; Mattke S; Haberl R; Steinbeck G
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):95-100. PubMed ID: 7678686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute, single, intravenous doses of cibenzoline: an evaluation of safety, tolerance, and hemodynamic effects.
    Humen DP; Lesoway R; Kostuk WJ
    Clin Pharmacol Ther; 1987 May; 41(5):537-45. PubMed ID: 3568538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cibenzoline plasma concentration and antiarrhythmic effect.
    Brazzell RK; Aogaichi K; Heger JJ; Somberg JC; Carliner NH; Morganroth J
    Clin Pharmacol Ther; 1984 Mar; 35(3):307-16. PubMed ID: 6697638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extremely prolonged elimination of cibenzoline at toxic plasma concentrations in patients with renal impairments.
    Takahashi M; Echizen H; Takahashi K; Shimada S; Aoyama N; Izumi T
    Ther Drug Monit; 2002 Aug; 24(4):492-6. PubMed ID: 12142632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral cibenzoline reduces postoperative atrial fibrillation in coronary artery bypass grafting.
    Kuriu K; Tanaka H; Hirao K; Makita S; Ito F; Mizuno T; Tabuchi N; Arai H; Sunamori M
    Jpn J Thorac Cardiovasc Surg; 2005 Jan; 53(1):8-15. PubMed ID: 15724496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of time of dosing on the disposition of oral cibenzoline.
    Brazzell RK; Khoo KC; Schneck DW
    Biopharm Drug Dispos; 1985; 6(4):433-40. PubMed ID: 4084668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.
    Klotz U; Müller-Seydlitz P; Heimburg P
    Clin Pharmacokinet; 1978; 3(5):407-18. PubMed ID: 699462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of rifampicin treatment on the kinetics of mexiletine.
    Pentikäinen PJ; Koivula IH; Hiltunen HA
    Eur J Clin Pharmacol; 1982; 23(3):261-6. PubMed ID: 6129140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart failure elevates serum levels of cibenzoline in arrhythmic patients.
    Kotake T; Takada M; Komamura K; Kamakura S; Miyatake K; Kitakaze M; Morishita H
    Circ J; 2006 May; 70(5):588-92. PubMed ID: 16636495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of dosing interval and optimum dose of cibenzoline.
    Zempol P; Aogaichi K; Butler B; Tepper D; Somberg JC
    J Clin Pharmacol; 1987 Sep; 27(9):666-72. PubMed ID: 3680596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction.
    Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Ushiogi Y; Nakamura S; Hashimoto N; Sasaki T; Satoh S
    Eur J Clin Pharmacol; 1991; 40(4):411-4. PubMed ID: 2050177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cibenzoline intoxication: effect of combined hemoperfusion-hemodialysis on plasma clearance.
    Meeus R; Verpooten GA; De Paep R; Paelinck BP; Neels H; Cooreman S; De Doncker M; Jorens PG
    Clin Toxicol (Phila); 2008 Apr; 46(4):303-6. PubMed ID: 18363124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics and dynamics of sematilide.
    Shi J; Lasser T; Koziol T; Hinderling PH
    Ther Drug Monit; 1995 Oct; 17(5):437-44. PubMed ID: 8585104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent].
    Atarashi H; Iida K; Kou M; Hirayama Y; Gotoh M; Ino T; Katoh T; Hayakawa H
    Kokyu To Junkan; 1988 Oct; 36(10):1119-24. PubMed ID: 3247527
    [No Abstract]   [Full Text] [Related]  

  • 35. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolism of 14C-cibenzoline in dogs and rats.
    Loh AC; Williams TH; Tilley JW; Sasso GJ; Szuna AJ; Carbone JJ; Toome V; Leinweber FJ
    Drug Metab Dispos; 1986; 14(3):325-30. PubMed ID: 2872033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of congestive heart failure on the pharmacokinetics of cibenzoline.
    Massarella JW; Silvestri T; DeGrazia F; Miwa B; Keefe D
    J Clin Pharmacol; 1987 Mar; 27(3):187-92. PubMed ID: 3680572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single infusion of intravenous cibenzoline in the treatment of supraventricular tachyarrhythmias following heart surgery. A double-blind placebo-controlled parallel study.
    Ollitrault J; Quilliet L; Scheck F; Lelong B; Richard A; Jarry G; Guize L
    Eur Heart J; 1994 Sep; 15(9):1274-8. PubMed ID: 7982430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.
    Trenk D; Wagner F; Sachs W; Jähnchen E
    Eur J Clin Pharmacol; 1989; 37(3):313-6. PubMed ID: 2612546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of cibenzoline, a class I antiarrhythmic drug, on action potential in canine ventricular muscle.
    Satoh H; Ishii M; Hashimoto K
    Jpn J Pharmacol; 1987 Jun; 44(2):113-9. PubMed ID: 3656771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.